IHC analyses of tumor tissues showed that afatinib, but not the anti‐CD47 antibody, treatment reduced the levels of EGFR p1068, c‐Src pY416, and CD47 expression (Figure S6E, Supporting Information). This evidence concerns the gene SRC and neoplasm.